JP2002506008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002506008A5 JP2002506008A5 JP2000535201A JP2000535201A JP2002506008A5 JP 2002506008 A5 JP2002506008 A5 JP 2002506008A5 JP 2000535201 A JP2000535201 A JP 2000535201A JP 2000535201 A JP2000535201 A JP 2000535201A JP 2002506008 A5 JP2002506008 A5 JP 2002506008A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- described method
- epc
- csf
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 description 60
- 241000124008 Mammalia Species 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 230000003511 endothelial effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 102100034594 Angiopoietin-1 Human genes 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 5
- 208000024248 Vascular System injury Diseases 0.000 description 5
- 208000012339 Vascular injury Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 108010048154 Angiopoietin-1 Proteins 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 239000000587 angiogenesis modulating agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7726298P | 1998-03-09 | 1998-03-09 | |
US60/077,262 | 1998-03-09 | ||
PCT/US1999/005130 WO1999045775A1 (en) | 1998-03-09 | 1999-03-09 | Compositions and methods for modulating vascularization |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010157554A Division JP2010265301A (ja) | 1998-03-09 | 2010-07-12 | 血管新生を調整するための組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002506008A JP2002506008A (ja) | 2002-02-26 |
JP2002506008A5 true JP2002506008A5 (de) | 2006-01-05 |
Family
ID=22137044
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000535201A Withdrawn JP2002506008A (ja) | 1998-03-09 | 1999-03-09 | 血管新生を調整するための組成物及び方法 |
JP2010157554A Pending JP2010265301A (ja) | 1998-03-09 | 2010-07-12 | 血管新生を調整するための組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010157554A Pending JP2010265301A (ja) | 1998-03-09 | 2010-07-12 | 血管新生を調整するための組成物及び方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1061800A4 (de) |
JP (2) | JP2002506008A (de) |
AU (1) | AU766238B2 (de) |
CA (1) | CA2322559C (de) |
WO (1) | WO1999045775A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2412436C (en) * | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
EP1294752A2 (de) * | 2000-06-16 | 2003-03-26 | Curis, Inc. | Zusammensetzungen zur modulierung der angiogenese und verwendung |
US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20020061587A1 (en) | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
CA2421966A1 (en) | 2000-09-13 | 2003-03-11 | Chugai Seiyaku Kabushiki Kaisha | Remedies for ischemic diseases |
WO2002035992A2 (en) * | 2000-10-30 | 2002-05-10 | Children's Medical Center Corporation | Tissue-engineered vascular structures |
WO2003043651A1 (en) * | 2001-11-19 | 2003-05-30 | Kyowa Hakko Kogyo Co., Ltd. | Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
JPWO2003059375A1 (ja) * | 2002-01-17 | 2005-05-19 | 株式会社カルディオ | 組織再生複合療法 |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
CN101391105A (zh) * | 2002-08-16 | 2009-03-25 | 舍林股份公司 | 以野生型或突变型eNOS对重症肢体缺血的基因治疗 |
US20040037811A1 (en) * | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
AU2008200822A1 (en) * | 2002-08-22 | 2008-03-13 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
CN100366257C (zh) * | 2002-08-22 | 2008-02-06 | 克里夫兰诊所基金会 | 基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生 |
CA2509618A1 (en) * | 2002-12-13 | 2004-07-01 | Hisayoshi Fujiwara | Pharmaceutical compositions for treating non-ischemic heart failure |
US7695723B2 (en) * | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
KR20070008714A (ko) * | 2004-04-30 | 2007-01-17 | 오르버스네이치 메디칼 인코포레이티드 | 유전적으로-변형된 세포 포획용 코팅을 갖는 의료 장치 및이의 사용 방법 |
US20090285785A1 (en) * | 2004-09-17 | 2009-11-19 | Cellgentech, Inc. | External Agent for Treatment of Skin Ulcer |
TW200637571A (en) * | 2005-01-11 | 2006-11-01 | Univ Nagoya Nat Univ Corp | CSF-containing remedy to be administered in low dose |
JPWO2006093172A1 (ja) * | 2005-02-28 | 2008-08-07 | 財団法人先端医療振興財団 | 成体幹細胞の体外増幅方法 |
ES2520044T3 (es) | 2007-03-30 | 2014-11-11 | The Cleveland Clinic Foundation | SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos |
CA2743184A1 (en) | 2007-11-09 | 2009-05-14 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof |
EP2227238A2 (de) | 2007-11-30 | 2010-09-15 | New York Medical College | Zusammensetzungen mit vaskulären und myozyten-vorläuferzellen und anwendungsverfahren davon |
US8124071B2 (en) | 2007-11-30 | 2012-02-28 | New York Medical College | Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
RU2470995C2 (ru) | 2008-04-09 | 2012-12-27 | Вайромед Ко., Лтд. | Лиофилизированные днк-составы для увеличенной экспрессии плазмидной днк |
CA2772610C (en) | 2009-08-28 | 2018-01-23 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
US9956265B2 (en) | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
KR101609690B1 (ko) * | 2011-04-26 | 2016-04-06 | 아주대학교산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
KR101336386B1 (ko) * | 2011-06-17 | 2013-12-04 | 전북대학교병원 | 림프관 생성 유도제 |
RU2639582C2 (ru) | 2013-10-22 | 2017-12-21 | Виромед Ко., Лтд. | Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов |
JP6860474B2 (ja) * | 2015-03-18 | 2021-04-14 | 公益財団法人神戸医療産業都市推進機構 | 虚血性疾患の治療及び/又は予防の為の医薬、細胞の血管新生促進活性向上方法、又は、医薬の製造方法 |
KR20210027493A (ko) | 2018-07-19 | 2021-03-10 | 주식회사 헬릭스미스 | 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808042A (en) * | 1982-06-11 | 1989-02-28 | Electro-Plasma, Inc. | Powder feeder |
US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US5880090A (en) * | 1997-09-19 | 1999-03-09 | The Hope Heart Institute | Treatment of vascular graft implants with G-CSF |
-
1999
- 1999-03-09 JP JP2000535201A patent/JP2002506008A/ja not_active Withdrawn
- 1999-03-09 CA CA2322559A patent/CA2322559C/en not_active Expired - Fee Related
- 1999-03-09 EP EP99912344A patent/EP1061800A4/de not_active Withdrawn
- 1999-03-09 WO PCT/US1999/005130 patent/WO1999045775A1/en active IP Right Grant
- 1999-03-09 AU AU30737/99A patent/AU766238B2/en not_active Ceased
-
2010
- 2010-07-12 JP JP2010157554A patent/JP2010265301A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002506008A5 (de) | ||
CA2322559A1 (en) | Compositions and methods for modulating vascularization | |
Liu et al. | Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors | |
JP3866197B2 (ja) | 虚血性疾患治療剤 | |
US20040161421A1 (en) | Intramyocardial injection of autologous bone marrow | |
DE60035035T2 (de) | Injektion von autologem knochenmark in den herzmuskel | |
Hayon et al. | The role of platelets and their microparticles in rehabilitation of ischemic brain tissue | |
Weaver et al. | The effects of axial displacement on fracture callus morphology and MSC homing depend on the timing of application | |
AU772857B2 (en) | Method of inducing angiogenesis | |
JP2007501282A (ja) | 哺乳類の四肢の細胞へのポリヌクレオチドの静脈内送達 | |
US20100034794A1 (en) | Endothelial progenitor cell compositions and neovascularization | |
JP2023105066A (ja) | 組織治癒剤 | |
KR20060052692A (ko) | 고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드 | |
US20060057722A1 (en) | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment | |
EP2431046B1 (de) | Verwendung von olivenblattextrakten in einer pharmazeutischen zusammensetzung zur induktion von angiogenese und vaskulogenese | |
AU2005282384B2 (en) | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment | |
JP4111950B2 (ja) | 自家骨髄の心筋内注射 | |
JP6923137B2 (ja) | 組織治癒剤 | |
CN113412118A (zh) | 用于预防支架内再狭窄的药物组合物 | |
CN101229366B (zh) | 成纤维细胞生长因子在制备促进血管生成药物中的应用 | |
CN100441226C (zh) | 用于加速创伤修复及防治并发症的方法 | |
Sprengers et al. | Growth factor and cell therapy in patients with critical limb ischemia | |
JP2003509463A (ja) | 肺系のための細胞ベースの遺伝子治療 |